A novel oral formulation of BIO 300 confers prophylactic radioprotection from acute radiation syndrome in mice

Int J Radiat Biol. 2022;98(5):958-967. doi: 10.1080/09553002.2021.1981556. Epub 2021 Sep 28.


Purpose: Exposure to high doses of ionizing radiation can result in hematopoietic acute radiation syndrome (H-ARS) and delayed effects of acute radiation exposure (DEARE). There is no radiation medical countermeasure (MCM) approved by the U.S. Food and Drug Administration which can be used prior to radiation exposure to protect exposed individuals. Different formulations containing synthetic genistein (BIO 300) are being developed to counter the harmful effects of radiation exposure.

Materials and methods: We investigated the efficacy of a BIO 300 oral powder (OP) formulation as a prophylactic radiation MCM against a lethal dose of cobalt-60 gamma-radiation in CD2F1 male mice while comparing to other formulations of BIO 300 and Neulasta (PEGylated filgrastim), a standard of care drug for H-ARS.

Results: BIO 300 OP provided significant radioprotection against ionizing radiation in mice when administered twice per day for six days prior to total-body radiation exposure. Its radioprotective efficacy in the murine model was comparable to the efficacy of a single subcutaneous (sc) injection of Neulasta administered after total-body radiation exposure.

Conclusions: Our results demonstrate that BIO 300 OP, which can be administered orally, is a promising prophylactic radiation countermeasure for H-ARS.

Keywords: Animal model; BIO 300; mice; prophylactic; radiation; radioprotection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Radiation Syndrome* / prevention & control
  • Animals
  • Dose-Response Relationship, Radiation
  • Female
  • Hematopoietic System*
  • Male
  • Mice
  • Radiation, Ionizing
  • Radiation-Protective Agents* / pharmacology
  • Whole-Body Irradiation


  • Radiation-Protective Agents